Stock A185490 EYEGENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials EyeGene Inc.

Equities

A185490

KR7185490000

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
3,110 KRW -.--% Intraday chart for EyeGene Inc. -4.01% -27.08%
2023 EyeGene Inc. announced that it has received KRW 15.000001688 billion in funding from BMI Korea Co., Ltd. CI
2023 EyeGene Inc. announced that it expects to receive KRW 15.000001688 billion in funding from BMI Korea Co., Ltd. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 157,772 132,693 148,527 408,921 108,036 91,605
Enterprise Value (EV) 1 132,165 111,394 133,299 327,508 43,978 39,444
P/E ratio -26.7 x -14.7 x -9.88 x -9.3 x -4.16 x -4.37 x
Yield - - - - - -
Capitalization / Revenue 77.5 x 31.3 x 44.2 x 126 x 20.4 x 29.3 x
EV / Revenue 64.9 x 26.2 x 39.6 x 101 x 8.31 x 12.6 x
EV / EBITDA -16.9 x -12.9 x -10.4 x -9.65 x -1.93 x -1.58 x
EV / FCF - -13,707,748 x -12,699,051 x -16,006,942 x -2,832,044 x -2,902,518 x
FCF Yield - -0% -0% -0% -0% -0%
Price to Book 6.76 x 6.97 x 11.5 x 4.6 x 1.62 x 1.82 x
Nbr of stocks (in thousands) 13,194 13,786 13,979 21,409 21,478 21,478
Reference price 2 11,958 9,625 10,625 19,100 5,030 4,265
Announcement Date 3/17/20 3/17/20 3/17/21 3/18/22 3/15/23 3/18/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2,035 4,245 3,363 3,242 5,293 3,125
EBITDA 1 -7,823 -8,652 -12,821 -33,934 -22,798 -24,949
EBIT 1 -8,266 -9,355 -13,675 -35,004 -24,089 -27,086
Operating Margin -406.13% -220.35% -406.57% -1,079.66% -455.07% -866.63%
Earnings before Tax (EBT) 1 -7,192 -8,740 -15,313 -34,653 -27,657 -22,430
Net income 1 -5,908 -8,740 -14,863 -34,569 -25,953 -21,106
Net margin -290.27% -205.88% -441.9% -1,066.25% -490.29% -675.3%
EPS 2 -448.2 -655.0 -1,075 -2,053 -1,210 -975.1
Free Cash Flow - -8,126 -10,497 -20,460 -15,529 -13,590
FCF margin - -191.42% -312.09% -631.08% -293.36% -434.81%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/17/20 3/17/20 3/17/21 3/18/22 3/15/23 3/18/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 25,607 21,299 15,228 81,413 64,058 52,161
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -8,126 -10,497 -20,460 -15,529 -13,590
ROE (net income / shareholders' equity) - -41.3% -93.1% -67.9% -33.5% -33.7%
ROA (Net income/ Total Assets) - -11.5% -18.6% -29.3% -16.2% -21.4%
Assets 1 - 75,757 79,767 118,050 159,775 98,797
Book Value Per Share 2 1,769 1,380 923.0 4,156 3,107 2,339
Cash Flow per Share 2 51.60 278.0 195.0 124.0 95.30 203.0
Capex 1 243 991 2,034 2,378 768 1,385
Capex / Sales 11.96% 23.34% 60.47% 73.34% 14.51% 44.33%
Announcement Date 3/17/20 3/17/20 3/17/21 3/18/22 3/15/23 3/18/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
EYEGENE INC. Stock EyeGene Inc.
-27.08% 60.75M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 699B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 571B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 326B
ABBVIE INC. Stock AbbVie Inc.
+3.77% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 236B
NOVARTIS AG Stock Novartis AG
+4.71% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 194B
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 154B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A185490 Stock
  4. Financials EyeGene Inc.